FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045292834> ?p ?o ?g. }

• W2045292834 endingPage "S212" @default.
• W2045292834 startingPage "S212" @default.
• W2045292834 abstract "RATIONALE: Omalizumab is a relatively novel therapy approved for treating patients with allergic moderate to severe persistent asthma. It is dosed subcutaneously every 2 - 4 weeks. We examined the efficacy of Omalizumab, in patients who demonstrated significant clinical response, after dosage intervals were extended. This was assessed based upon the proposed half life of IgG being 28 days.METHODS: An IRB approved prospective analysis was performed to assess the efficacy of extended dose intervals of Omalizumab in 31 patients with allergic diseases including persistent asthma, urticaria, angioedema/anaphylaxis, and atopic dermatitis. Quality of life measurements were completed using Juniper Quality of Life measurements.RESULTS: Sixteen female and 15 male patients ranging from 13-80 years old (mean age = 45.1 years), were evaluated in a private practice setting. Their mean IgE level was 779 IU/mL. Of these 31 patients, 29 (94%) demonstrated clinical efficacy after lengthening their dosage interval. 17 of the twenty nine patients started with every 2 weeks dosing, and they were able to extend their Omalizumab dose on average after their ninth dose. 12 of the twenty nine patients started with every 4 weeks dosing, and they were able to extend their Omalizumab dose on average after their eleventh dose.CONCLUSIONS: Extension of dosing intervals of Omalizumab was successful based upon clinical response and maintenance scheduling. This appears likely after the patient's reach steady state concentrations of Omalizumab. Earlier success was noted in those patients who initially received their Omalizumab every two weeks, however lengthening dosage intervals was successful in both groups. RATIONALE: Omalizumab is a relatively novel therapy approved for treating patients with allergic moderate to severe persistent asthma. It is dosed subcutaneously every 2 - 4 weeks. We examined the efficacy of Omalizumab, in patients who demonstrated significant clinical response, after dosage intervals were extended. This was assessed based upon the proposed half life of IgG being 28 days. METHODS: An IRB approved prospective analysis was performed to assess the efficacy of extended dose intervals of Omalizumab in 31 patients with allergic diseases including persistent asthma, urticaria, angioedema/anaphylaxis, and atopic dermatitis. Quality of life measurements were completed using Juniper Quality of Life measurements. RESULTS: Sixteen female and 15 male patients ranging from 13-80 years old (mean age = 45.1 years), were evaluated in a private practice setting. Their mean IgE level was 779 IU/mL. Of these 31 patients, 29 (94%) demonstrated clinical efficacy after lengthening their dosage interval. 17 of the twenty nine patients started with every 2 weeks dosing, and they were able to extend their Omalizumab dose on average after their ninth dose. 12 of the twenty nine patients started with every 4 weeks dosing, and they were able to extend their Omalizumab dose on average after their eleventh dose. CONCLUSIONS: Extension of dosing intervals of Omalizumab was successful based upon clinical response and maintenance scheduling. This appears likely after the patient's reach steady state concentrations of Omalizumab. Earlier success was noted in those patients who initially received their Omalizumab every two weeks, however lengthening dosage intervals was successful in both groups." @default.
• W2045292834 created "2016-06-24" @default.
• W2045292834 creator A5018275182 @default.
• W2045292834 creator A5028608279 @default.
• W2045292834 creator A5035409496 @default.
• W2045292834 creator A5039382729 @default.
• W2045292834 creator A5060219345 @default.
• W2045292834 creator A5066981637 @default.
• W2045292834 creator A5079918052 @default.
• W2045292834 date "2007-01-01" @default.
• W2045292834 modified "2023-09-26" @default.
• W2045292834 title "Efficacy of Omalizumab Using Extended Dose Intervals" @default.
• W2045292834 doi "https://doi.org/10.1016/j.jaci.2006.12.199" @default.
• W2045292834 hasPublicationYear "2007" @default.
• W2045292834 type Work @default.
• W2045292834 sameAs 2045292834 @default.
• W2045292834 citedByCount "7" @default.
• W2045292834 countsByYear W20452928342013 @default.
• W2045292834 countsByYear W20452928342014 @default.
• W2045292834 countsByYear W20452928342015 @default.
• W2045292834 countsByYear W20452928342018 @default.
• W2045292834 countsByYear W20452928342019 @default.
• W2045292834 crossrefType "journal-article" @default.
• W2045292834 hasAuthorship W2045292834A5018275182 @default.
• W2045292834 hasAuthorship W2045292834A5028608279 @default.
• W2045292834 hasAuthorship W2045292834A5035409496 @default.
• W2045292834 hasAuthorship W2045292834A5039382729 @default.
• W2045292834 hasAuthorship W2045292834A5060219345 @default.
• W2045292834 hasAuthorship W2045292834A5066981637 @default.
• W2045292834 hasAuthorship W2045292834A5079918052 @default.
• W2045292834 hasBestOaLocation W20452928341 @default.
• W2045292834 hasConcept C126322002 @default.
• W2045292834 hasConcept C141071460 @default.
• W2045292834 hasConcept C141105273 @default.
• W2045292834 hasConcept C159654299 @default.
• W2045292834 hasConcept C203014093 @default.
• W2045292834 hasConcept C207480886 @default.
• W2045292834 hasConcept C2775933838 @default.
• W2045292834 hasConcept C2776042228 @default.
• W2045292834 hasConcept C2777288759 @default.
• W2045292834 hasConcept C2777995640 @default.
• W2045292834 hasConcept C2778564945 @default.
• W2045292834 hasConcept C27924281 @default.
• W2045292834 hasConcept C71924100 @default.
• W2045292834 hasConceptScore W2045292834C126322002 @default.
• W2045292834 hasConceptScore W2045292834C141071460 @default.
• W2045292834 hasConceptScore W2045292834C141105273 @default.
• W2045292834 hasConceptScore W2045292834C159654299 @default.
• W2045292834 hasConceptScore W2045292834C203014093 @default.
• W2045292834 hasConceptScore W2045292834C207480886 @default.
• W2045292834 hasConceptScore W2045292834C2775933838 @default.
• W2045292834 hasConceptScore W2045292834C2776042228 @default.
• W2045292834 hasConceptScore W2045292834C2777288759 @default.
• W2045292834 hasConceptScore W2045292834C2777995640 @default.
• W2045292834 hasConceptScore W2045292834C2778564945 @default.
• W2045292834 hasConceptScore W2045292834C27924281 @default.
• W2045292834 hasConceptScore W2045292834C71924100 @default.
• W2045292834 hasIssue "1" @default.
• W2045292834 hasLocation W20452928341 @default.
• W2045292834 hasOpenAccess W2045292834 @default.
• W2045292834 hasPrimaryLocation W20452928341 @default.
• W2045292834 hasRelatedWork W1966683997 @default.
• W2045292834 hasRelatedWork W2072685431 @default.
• W2045292834 hasRelatedWork W2085552858 @default.
• W2045292834 hasRelatedWork W2088215603 @default.
• W2045292834 hasRelatedWork W2107604311 @default.
• W2045292834 hasRelatedWork W2333164741 @default.
• W2045292834 hasRelatedWork W2781798643 @default.
• W2045292834 hasRelatedWork W2801936878 @default.
• W2045292834 hasRelatedWork W4284681976 @default.
• W2045292834 hasRelatedWork W86134801 @default.
• W2045292834 hasVolume "119" @default.
• W2045292834 isParatext "false" @default.
• W2045292834 isRetracted "false" @default.
• W2045292834 magId "2045292834" @default.
• W2045292834 workType "article" @default.